Drug profile

The FDA adverse-event record for Florfenicol + Terbinafine + Mometasone Furoate

21 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Florfenicol + Terbinafine + Mometasone Furoate. See the species affected, top reactions, and outcomes below.

21
adverse-event reports
9.5%
death-coded share
Dog
most-reported species
7
Vomiting - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
21
Total Reports
2
Deaths Reported
9.5%
Death Rate

Active Ingredients

Florfenicol + Terbinafine + Mometasone Furoate

Administration Routes

Auricular (Otic)Unknown

Species Affected

Dog 21

Most Affected Breeds

Retriever - Labrador 3
Spaniel - Cocker American 2
Shiba Inu 1
Terrier (unspecified) 1
Schnauzer (unspecified) 1
Terrier - Yorkshire 1
Retriever - Golden 1
Bulldog 1
Pit Bull 1
Unknown 1

Most Reported Reactions

Vomiting 7
Decreased urine concentration 2
Death 2
Lack of efficacy - NOS 2
Ear infection NOS 2
Lethargy (see also Central nervous system depression in Neurological) 2
Diarrhoea 2
Vestibular disorder NOS 1
Head tilt - ear disorder 1
Tremor 1
Hind limb ataxia 1
Proprioception deficit 1

Outcome Breakdown

Recovered/Normal
7 (33.3%)
Outcome Unknown
7 (33.3%)
Ongoing
5 (23.8%)
Died
2 (9.5%)

Florfenicol + Terbinafine + Mometasone Furoate Adverse Event Insights

21 reports name Florfenicol + Terbinafine + Mometasone Furoate; 2 recorded a death outcome (9.5% of reported events, not a population-level mortality rate). Active ingredient: Florfenicol + Terbinafine + Mometasone Furoate. Administration routes: Auricular (Otic), Unknown.

By species: Dog (21 reports). By breed: Retriever - Labrador (3), Spaniel - Cocker American (2), Shiba Inu (1).

Leading clinical signs: Vomiting (7), Decreased urine concentration (2), Death (2), Lack of efficacy - NOS (2). Outcome, 21 coded reports: Recovered/Normal leads at 33.3%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.